InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
5
Disclosed sells
4
T+90 hit rate
0%
T+90 mean return
-21.3%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Kunin Audrey, Directeur Produit. Insider active across 1 company, notably NovaBay Pharmaceuticals, Inc.. Aggregated, 9 filings have been recorded. Breakdown: 5 buys · 4 sells. Total volume traded: €251k. History available since 22 November 2021. The latest transaction was disclosed on 6 December 2022 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations9 total
1 shares@ US$1.810.0% of flowCommon StockSEC:0001437749-22-028673:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028439:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028031:0
291,368 shares@ US$0.158210.7% of flowCommon StockSEC:0001437749-22-022646:0
101,650 shares@ US$0.46250.080% mcap11.5% of flowCommon StockSEC:0001437749-21-028027:0
Canonical exit: 3 Mar 2022 (T+90)
262,369 shares@ US$0.4760.21% mcap30.5% of flowCommon StockSEC:0001437749-21-027934:0
Canonical exit: 2 Mar 2022 (T+90)
14,848 shares@ US$0.490.012% mcap1.8% of flowCommon StockSEC:0001437749-21-027852:0
Canonical exit: 1 Mar 2022 (T+90)
30,000 shares@ US$0.460.024% mcap3.4% of flowCommon StockSEC:0001437749-21-027706:0
Canonical exit: 28 Feb 2022 (T+90)
25,000 shares@ US$0.460.020% mcap2.8% of flowCommon StockSEC:0001437749-21-027397:0
Canonical exit: 20 Feb 2022 (T+90)
9 of 9 declarations
About Kunin Audrey
Audrey Kunin is the Chief Product Officer at NovaBay Pharmaceuticals, Inc. She oversees the development of new products and innovation within the company. Her expertise in research and development is essential for the success of the company's initiatives. Audrey is committed to improving patient outcomes through innovative solutions.
